Target intelligence / Profile preview

T cell receptor recognizing Influenza A virus Hemagglutinin (H1) peptides in the context of MHC class II (H1-specific TCR)

Target
H1-specific TCR
Molecular classification
T cell receptor, Antigen-recognizing receptor, Receptor
01

Overview

The T cell receptor (TCR) recognizing H1-derived peptides in the context of MHC class II is a critical component of the adaptive immune response against Influenza A virus, specifically the H1 subtype. These TCRs are primarily expressed on CD4+ T helper cells and recognize peptide fragments derived from the viral hemagglutinin (HA) protein presented by Major Histocompatibility Complex (MHC) class II molecules, such as HLA-DR or HLA-DQ. This recognition event is essential for 'linked recognition,' a process where H1-specific T cells provide the necessary signals, including CD40 ligand and cytokines, to B cells to promote high-affinity antibody production and the establishment of long-term humoral immunity. In the context of drug development, these TCRs are primary targets for universal influenza vaccines designed to elicit broad, cross-reactive T cell help across different viral strains. They are also being explored as therapeutic agents in TCR-engineered T cell (TCR-T) therapies for severe viral infections. However, these TCRs are associated with significant safety considerations, most notably molecular mimicry between H1 peptides and self-antigens like hypocretin, which has been implicated in the development of narcolepsy following certain H1N1 vaccinations.

Other names
HA-specific T-cell receptorHemagglutinin-specific T-cell receptorInfluenza H1-specific TCRCD4+ T-cell receptor for H1H1-peptide-MHC-II-specific TCR
02

Mechanism of action

Activation of CD4+ T cells through the recognition of H1-derived peptides presented by MHC class II, facilitating B cell help and antibody production.

03

Biological functions

Immune responseAntigen recognitionT cell activationT-B cell collaborationLinked recognition
04

Disease associations

InfectionInflammationOther
05

Safety considerations

Molecular mimicry with self-antigens (e.g., hypocretin/orexin in narcolepsy)Cytokine release syndrome (in TCR-T therapy)MHC restriction (therapeutic efficacy limited to specific HLA alleles)
06

Interacting drugs

Influenza A virus vaccine

3 more in the full profile.

07

Biomarkers

H1-specific CD4+ T cell frequencyIFN-gamma production upon H1 peptide stimulationHLA-DRB1*01:01HLA-DQB1*06:02

Beyond the preview

Go deeper on T cell receptor recognizing Influenza A virus Hemagglutinin (H1) peptides in the context of MHC class II (H1-specific TCR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor recognizing Influenza A virus Hemagglutinin (H1) peptides in the context of MHC class II (H1-specific TCR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call